Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
OTC Markets OTCQB - Delayed Quote USD

Sigyn Therapeutics, Inc. (SIGY)

Compare
4.1200
0.0000
(0.00%)
At close: February 21 at 3:00:00 PM EST

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. James A. Joyce Ph.D. Co-founder, Chairman & CEO Inventor 486.04k -- 1962
Mr. Craig P. Roberts Co-founder & Director 256.46k -- 1954
Mr. Gerald DeCiccio CPA, M.B.A. Chief Financial Officer 128.77k -- 1958
Ms. Charlene R. Owen Director of Operations -- -- --
Dr. Annette Marleau Ph.D. Chief Scientific Officer -- -- 1975
Mr. Johan Louw Senior Vice President of Strategic Programs -- -- --

Sigyn Therapeutics, Inc.

2468 Historic Decatur Road
Suite 140
San Diego, CA 92106
United States
619 353 0800 https://www.sigyntherapeutics.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
5

Description

Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.

Corporate Governance

Sigyn Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

January 16, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 6, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 19, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

November 15, 2024 at 12:00 AM UTC

NT 10-Q: Periodic Financial Reports

October 16, 2024 at 12:00 AM UTC

8-K/A: Corporate Changes & Voting Matters

October 7, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 30, 2024 at 12:00 AM UTC

RW: Registration Withdrawal Request

August 19, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

August 14, 2024 at 12:00 AM UTC

NT 10-Q: Periodic Financial Reports

June 6, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers